
To evaluate the efficacy and safety of iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes (T2D), advancing therapy from basal insulin ± oral antihyperglycaemic drugs. iGlarLixi provided better glycaemic control and facilitated more participants to reach glycaemic targets alongside beneficial effects on body weight, with no additional risk of hypoglycaemia. Few gastrointestinal AEs, support iGlarLixi use as an efficacious and well-tolerated therapy option in Chinese people with long‐standing T2D advancing therapy from basal insulin.
Like
Save
Share